Artikel ; Online: PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2021 Band 146, Seite(n) 112519
Abstract: Introduction: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to ... ...
Abstract | Introduction: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to other lipid-lowering drugs. Our aim was to analyze the effectiveness and safety of PCSK9i in routine clinical practice and factors related to poor outcomes. Materials and methods: We conducted an ambispective study in 115 patients who recieved alirocumab or evolocumab, in a tertiary level hospital. From February 2017 to April 2020, patients were recruited and followed up for a median of 20.4 months. The main outcomes were relative reduction in LDL-C, percentage of patients achieving the therapeutic goals established by 2016 ESC/EAS guidelines, incidence of major cardiovascular events (MACEs) and drug-related adverse events (ADRs). Results: The median LDL-C achieved was 57.0 mg/dL (relative reduction of 59.9% from baseline, p< 0.001). After adjusting for confounders, smaller LDL-C reductions were related to female sex, absence of concomitant lipid-lowering therapy and treatment with alirocumab. Overall, 84.6% of the patients achieved the therapeutic goals. During follow-up, 7 MACEs were detected. ADRs, generally considered mild, affected 38.1% of the participants (mainly mialgias and arthralgias) and triggered discontinuations in 8.7% of cases. Conclusions: PCSK9i are effective and safe, although certain factors may influence their effectiveness. Interestingly, our results suggest that alirocumab and evolocumab may not be therapeutic equivalents, as initially suggested. |
---|---|
Mesh-Begriff(e) | Age Factors ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/therapeutic use ; Cardiovascular Diseases/epidemiology ; Comorbidity ; Dose-Response Relationship, Drug ; Female ; Humans ; Hypercholesterolemia/drug therapy ; Life Style ; Lipids/blood ; Male ; Middle Aged ; PCSK9 Inhibitors/administration & dosage ; PCSK9 Inhibitors/adverse effects ; PCSK9 Inhibitors/therapeutic use ; Sex Factors ; Spain |
Chemische Substanzen | Antibodies, Monoclonal, Humanized ; Anticholesteremic Agents ; Lipids ; PCSK9 Inhibitors ; evolocumab (LKC0U3A8NJ) ; alirocumab (PP0SHH6V16) |
Sprache | Englisch |
Erscheinungsdatum | 2021-12-28 |
Erscheinungsland | France |
Dokumenttyp | Journal Article |
ZDB-ID | 392415-4 |
ISSN | 1950-6007 ; 0753-3322 ; 0300-0893 |
ISSN (online) | 1950-6007 |
ISSN | 0753-3322 ; 0300-0893 |
DOI | 10.1016/j.biopha.2021.112519 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Ud II Zs.198: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.